RMED's went public 2.19 years ago, making it older than just 5.21% of listed US stocks we're tracking.
The volatility of Ra Medical Systems Inc's share price is greater than that of 99.62% US stocks with at least 200 days of trading history.
Ra Medical Systems Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -126.53%, greater than the shareholder yield of only 3% of stocks in our set.
If you're looking for stocks that are quantitatively similar to Ra Medical Systems Inc, a group of peers worth examining would be ECOR, TWOU, XENT, LEAF, and WEI.
RMED's SEC filings can be seen here. And to visit Ra Medical Systems Inc's official web site, go to www.ramed.com.
RA Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light used in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was founded in 2002 and is based in Carlsbad, California.
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Sutro Biopharma Inc (NASDAQ: STRO ) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) Akebia Therapeutics Inc (NASDAQ: AKBA ) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Genfit SA (NASDA...
Ra Medical Systems, Inc. (RMED) Q2 2020 Earnings Conference Call August 11, 2020, 16:30 ET Company Participants Jody Cain - Lippert/Heilshorn & Associates Jonathan McGuire - CEO & Director Andrew Jackson - CFO Conference Call Participants Andrew Stafford - Piper Sandler & Co. Anthony Vendetti - Maxim Group Presentation Operator...
Ra Medical Systems ([[RMED]] -10.9%) priced public offering of 34.3M shares, along with its accompanying warrants, at $0.35/share; gross proceeds of ~$12M.Warrants, immediately exercisable, have an exercise price of $0.35/share; five years expiry from issuance date.Offering is expected to close on or about August 3, 2020.Proceeds will be used for...
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (“Ra Medical”) (NYSE: RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases, today announced that it has priced a public offering of an aggregate of 34,285,714 shares of common stock (or common stock equivalents), together with accompanying warrants to purchase up to an aggregate of 34,285,714 sh
LOS ANGELES--(BUSINESS WIRE)---- $RMED #classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Ra Medical Systems, Inc. (“Ra Medical” or the “Company”) (NYSE: RMED) concerning whether the board breached its fiduciary duty to shareholders. If you are a shareholder, click here for more information. Follow us for updates on Twitter: twitter.com/FRC_LAW. If you purchased Ra Medical securities, have information or would like to learn more about these claims, or ha